The following table is for layout only Goto Main Navigation | Goto Main Content | Goto Banner | Goto Logon Box | Goto Menu Bar | Goto Search Box | Goto Footer
 

 
Register
|
Return to Listing
Intravenous immunoglobulin for delayed hyperhaemolysis syndrome following exchange transfusion in a patient with sickle cell disease
URL/File
 IVIG for haemolysis.doc [62.5K]​ - Downloaded once. Last downloaded 08 Jun 2012 11:01.
FormatMS Word Document (.doc)
Home LocationLHO
National or RegionalRegional
start of decorative frame for
start of content for
Publication date17 Aug 2010
Creator(s)Lambeth PCT, London and South East Medicines Information Unit
end of content for
end of decorative frame for
start of decorative frame for
start of content for
Is part of
end of content for
end of decorative frame for
start of decorative frame for
start of content for
Intravenous immunoglobulin (IVIG) for multiple sclerosis (MS)
Intravenous immunoglobulin for the treatment of parainfluenza 3 virus
NHS Sickle Cell & Thalassaemia Screening Programme Homepage
Intravenous immunoglobulin for a 65 year old patient with pyoderma gangrenosum, for which standard treatments have failed
Lenalidomide, 2nd line therapy, for a patient with aggressive epidermotropic CD8+ peripheral cutaneous T cell Non Hodgkin’s Lymphoma, post allogeneic stem cell transplant to stabilise disease prior to donor lymphocyte infusion
More...
end of content for
end of decorative frame for
start of decorative frame for
start of content for
KeywordsClinical exceptions
Exceptional treatments
Hyperhaemolysis syndrome
Individual funding requests
individual treatments
intravenous immunoglobulin
IVIG
Sickle cell disease
end of content for
end of decorative frame for
start of decorative frame for Type and Language
Type and Language
start of content for Type and Language
Resource Typereport
end of content for Type and Language
end of decorative frame for Type and Language